Almost everything written about these two brands is really about two molecules, and it ends at the same trial result. That result matters, it is covered in detail on our tirzepatide vs semaglutide page, and repeating it here would answer a question that has already been answered.
The brands are a different subject. Zepbound is Eli Lilly's tirzepatide; Wegovy is Novo Nordisk's semaglutide. What separates them as products — who can be prescribed each, what device arrives, what it costs, and which plan door is open — comes almost entirely from what each label approves. And on that measure the two are not symmetrical at all.
Both labels were read on 12 September 2026 from DailyMed, the National Library of Medicine's index of current FDA labelling. Nothing here is medical advice, and nothing here is a dose or a schedule; what a person should take belongs with a prescriber, for the reasons our editorial standards set out.
What each brand is actually approved to treat
| Zepbound | Wegovy (injection) | Wegovy (tablet) | |
|---|---|---|---|
| Long-term weight reduction, adults with obesity or overweight plus a comorbidity | Yes | Yes | Yes |
| Weight reduction, patients aged 12 and older with obesity | — | Yes | — |
| Reduction of major adverse cardiovascular event risk | — | Yes | Yes |
| Moderate to severe obstructive sleep apnoea in adults with obesity | Yes | — | — |
| Noncirrhotic MASH with moderate to advanced fibrosis (F2–F3) | — | Yes (accelerated approval) | — |
Label revisions: Zepbound 28 August 2026; Wegovy 18 June 2026.
Three things in that table are worth stating in words, because each is routinely lost in comparisons of these brands.
Wegovy holds more doors, and one of them is not a full approval. The MASH indication is granted under accelerated approval — the pathway that permits approval on a surrogate endpoint while confirmatory evidence is still required. It is a genuine approval and it is a different kind of approval from the other three, and the label marks it as such. A comparison that lists four Wegovy indications against two for Zepbound without noting which one is provisional has counted correctly and described inaccurately.
Only one of the two brands reaches adolescents. The Wegovy injection is indicated for patients aged 12 and older with obesity. Both Zepbound indications are adults only. For a family comparing the two, that is not a nuance — it removes one of them from the comparison entirely.
"Wegovy" is two products with two sets of approvals. The injection and the tablet sit under one brand and one label document, but the tablet carries only the cardiovascular and adult-weight indications. No paediatric use, no MASH. Someone offered "the Wegovy pill" as an alternative to Zepbound is being offered a narrower label than the pen — the same brand, a different set of approved uses.
What arrives in the box
The devices differ more than the marketing suggests, and in a direction that inverts the usual assumption about which brand is the more modern one.
Zepbound is supplied as single-dose pens, single-dose vials, multi-dose vials, and a KwikPen holding 2.4 mL as four doses. Wegovy is supplied as single-dose pens and prefilled syringes, a FlexTouch multi-dose pen, and tablets.
So the brand without an oral form is the brand that offers a vial, and the brand with a pill is the one that does not. Lilly's self-pay route explicitly runs through the KwikPen or the vial rather than the single-dose pen, which is why the cheapest published Zepbound figure and the most convenient Zepbound device are not the same purchase. Our Zepbound cost page works through which price attaches to which presentation.
Both labels carry the same limitation of use, in nearly identical wording: neither product is recommended alongside another product containing the same molecule, or alongside any other GLP-1 receptor agonist.
Why "which is cheaper" has no single answer
Both brands publish a headline self-pay figure, and both quote it at the bottom of their strength range. Only one of them then holds that price as the strength rises.
| Cheapest published self-pay | Does the price move with strength? | |
|---|---|---|
| Zepbound | $299 (LillyDirect, quoted at the 2.5 mg starting strength) | Yes — KwikPen $299 / $399 / $449 by strength; $499 without coverage |
| Wegovy | $349 pen, or $149 tablet at 1.5 mg | No for the injection — $349 covers 0.25 mg through 2.4 mg alike; HD 7.2 mg pen $399 |
Figures read 8 September 2026 from the manufacturers' own published material; full terms and their conditions are on the Zepbound and Wegovy pages, and the cost hub keeps the whole category's table.
The consequence is that the two cannot be ranked by price in the abstract. Zepbound starts $50 cheaper and rises; Wegovy starts higher and does not move. Which one is less expensive over a year depends on where a strength settles — and, on the Zepbound side, on a refill condition: the $449 offer requires each refill to be completed within 45 days of the previous delivery, against a $699 regular price at the higher strengths. That is a term, not a discount, and it is the single largest swing in either brand's published pricing.
Coverage follows the indication, not the brand
This is where the label table stops being an administrative detail. Coverage decisions turn on the indication a prescription is written under and whether the supporting diagnosis is documented — which means the two brands' different non-weight indications are different alternative routes when a plan excludes weight-loss use.
Zepbound's second door is obstructive sleep apnoea. Wegovy's are cardiovascular risk reduction and, more narrowly, MASH. Neither is a workaround: each is an approved indication requiring the condition to be present and documented. The statutory mechanism behind all of this — including the fact that Congress wrote the identical structure deliberately for a different drug class — is set out on our insurance coverage page.
What this page does not answer
It does not say which brand anyone should be prescribed, and it contains no dose and no schedule. It also does not settle the efficacy question, which belongs to the molecules rather than the brands and rests on a single open-label trial funded by one of the two manufacturers; that trial, and the four design facts that limit it, are on the tirzepatide vs semaglutide page.
What it does establish is that the two brands are not interchangeable objects that differ only in which molecule is inside. They approve different uses, reach different age groups, arrive in different devices, and price along different curves — and every one of those differences is readable from a label or a manufacturer's own published terms.
Sources
- DailyMed, ZEPBOUND (tirzepatide) injection, solution / ZEPBOUND KwikPen, Eli Lilly and Company. SPL version 40, label revised 28 August 2026 — read 12 September 2026. Indications, limitation of use, dosage forms and presentations.
- DailyMed, WEGOVY (semaglutide) injection, solution / WEGOVY (semaglutide) tablet, Novo Nordisk Pharmaceutical Industries, LP. SPL version 19, label revised 18 June 2026 — read 12 September 2026. Indications for both dosage forms, limitation of use, strengths.
- Price figures are not re-derived here. They are carried from our Zepbound and Wegovy cost pages, where each was read from the manufacturer's own published material on 8 September 2026 and is quoted with its terms.
Prices and labels in this category both change. Every figure above carries the date it was read; the manufacturer's page and the current label are the only reliable sources for the position today.